Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets
angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated
kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant
inhibitory activities.